cancer is a complex group of diseases driven by genetic mutations that cause cells to evade normal regulatory mechanisms, leading to uncontrolled proliferation, evasion of apoptosis, and the ability to invade surrounding tissues and metastasize to distant organs. It is distinguished from a benign neoplasm, which may grow locally but lacks the capacity for tissue invasion and distant metastasis. The underlying pathological mechanism typically involves the activation of oncogenes and the inactivation of tumor suppressor genes, resulting in structural and molecular cellular abnormalities. While all cancers are pathological, they are broadly categorized by their tissue of origin into clinically relevant subtypes such as carcinomas (epithelial origin, e.g., C61 for prostate), sarcomas (mesenchymal origin, e.g., C49.x for connective tissue), leukemias (blood-forming tissue), and lymphomas (lymphatic system). cancer is commonly confused with the broader term “tumor,” but it is vital to note that while all cancers (solid) form tumors, not all tumors are cancerous (malignant).
The word entered English in the 14th century as cancer (noun), borrowed from Old French chancre, from Latin cancer, from Greek karkinos — literally “crab.” The ancient Greek physician Hippocrates first used the term karkinos to describe carcinoma tumors because the swollen blood vessels radiating from the central mass resembled the limbs of a crab. The root carcino- (“crab/cancer”) connects Cancer to the entire carcino- ROOT FAMILY: carcinogenesis (creation of cancer), carcinogen (cancer-causing agent), and carcinoma (malignant tumor of epithelial tissue). The prefix/root onco- is highly productive in medical terminology, appearing in oncology, oncogene, and oncologist.
🔀 ALIASES / ALTERNATE TERMS
Malignant(adjective form — e.g., “malignant neoplasm,” “malignant transformation”)
Malignancy(clinical synonym; widely used across all specialties to denote cancerous growth)
Carcinoma in situ (CIS)(pre-invasive or non-invasive form of the condition; confined to the site of origin without basement membrane penetration)
Primary Malignant Neoplasm(clinical descriptor synonym; coded under C00-C75, C81-C96, denoting the original site of the tumor)
Secondary Malignant Neoplasm(metastatic form; C77-C79, denoting spread to a distant site)
Carcinoma(epithelial subtype; the most common type of cancer, affecting organs and glands)
Sarcoma(mesenchymal subtype; cancer of bone, cartilage, fat, muscle, or blood vessels)
Urothelial Carcinoma(organ/tissue-specific form; C67.x; most common type of bladder cancer)
Squamous Cell Carcinoma (SCC)(organ/tissue-specific form; C32.x; highly prevalent in head and neck/otolaryngology cancers)
Retinoblastoma(organ/tissue-specific form; C69.2x; malignant tumor of the retina, primarily affecting children)
Choroidal Melanoma(organ/tissue-specific form; C69.3x; most common primary intraocular malignancy in adults)
🔗 RELATED TERMS
Benign Neoplasm — the opposite of cancer in terms of behavior; a localized cellular proliferation that does not invade adjacent tissues or metastasize.
Dysplasia — shares the -plasia (growth/formation) concept; abnormal development or growth of cells, tissues, or organs, often a precursor to cancer.
Metastasis — the physiological mechanism by which cancer cells break away from the primary tumor, travel through the blood or lymph system, and form new tumors in other organs (C77-C79).
Paraneoplastic Syndrome — complex syndrome triggered by an altered immune system response to a neoplasm; often presents with neurological or endocrine symptoms independent of the local tumor effects.
Angiogenesis — the physiological mechanism of developing new blood vessels, which tumors hijack to supply themselves with nutrients and oxygen for rapid growth.
Oncogenic — adjective describing viral, genetic, or environmental inputs that induce or sustain malignant transformation.
Apoptosis — programmed cellular death; a normal regulatory process that cancer cells pathologically evade to achieve immortality.
Cachexia — systemic wasting syndrome often malignancy-related (R64); characterized by severe weight loss and muscle atrophy, frequently requiring PM&R intervention.
Pathological Fracture — another clinical entity defined by this term at a specific anatomic site; a bone break caused by disease (like metastatic cancer) rather than trauma (M84.5x).
Lymphedema — another clinical entity; often a secondary complication following surgical lymph node dissection or radiation therapy for cancer (I89.0).
Biopsy — primary or key diagnostic tool for evaluating and definitively diagnosing cancer through histopathological examination.
Destruction of localized lesion of retina (eg, macular edema, tumors), 1 or more sessions; radiation by application of source (includes removal of source) (Ophthalmology)
Therapeutic procedure, 1 or more areas, each 15 minutes; therapeutic exercises to develop strength and endurance, range of motion and flexibility (PM&R - Cancer Rehab)
Therapeutic procedure, 1 or more areas, each 15 minutes; neuromuscular reeducation of movement, balance, coordination, kinesthetic sense, posture, and/or proprioception for sitting and/or standing activities (PM&R - Cancer Rehab)
Therapeutic activities, direct (one-on-one) patient contact (use of dynamic activities to improve functional performance), each 15 minutes (PM&R - Cancer Rehab)
⚠️ Coding Note:Inpatient profee coding for malignancies requires strict adherence to sequencing guidelines regarding primary vs. secondary sites and the specific reason for the encounter. If the admission/encounter is solely for the administration of chemotherapy, immunotherapy, or radiation therapy, assign the appropriate Z51.- code as the principal diagnosis, followed by the active malignancy code. If the encounter is directed at treating a secondary (metastatic) site, the secondary neoplasm is sequenced first, followed by the primary site. A common undercoding alert in PM&R and inpatient rehab settings involves missing the functional deficits caused by the cancer or its treatment; documentation triggers like “generalized weakness,” “cancer cachexia,” or “deconditioning” should prompt a query to link the functional impairment (e.g., M62.81 Muscle weakness) to the malignancy to support the medical necessity of intensive therapy. Furthermore, do not code an active malignancy if the cancer has been excised or eradicated and the patient is no longer receiving adjunct treatment; use the appropriate “Personal history of” (Z85.-) code instead.